<?xml version="1.0" encoding="UTF-8"?>
<p id="Par38">A multicenter, open-label, randomized controlled trial of 150 patients with mild–moderate COVID-19 revealed that antimalarial drugs led to a similar probability of virus eradication when compared to standard care, establishing neither benefits nor significant increase of risks, discouraging the use of HCQ in those patients [
 <xref ref-type="bibr" rid="CR24">24</xref>]. However, in a cohort study of 90 hospitalized patients with COVID-19, patients taking HCQ and azithromycin had greater QT interval prolongation than those taking HCQ alone [
 <xref ref-type="bibr" rid="CR25">25</xref>].
</p>
